Oscotec Inc.

Translating science into medicine
Sign Up
FLT3/AXL Inhibitor (A... 2020.06.22  
  1. No Image 01Jun

    Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

  2. No Image 01Jun

    Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

  3. No Image 01Jun

    Yuhan to start phase-3 trial on lung cancer drug Lazertinib

  4. No Image 01Jun

    "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

  5. No Image 01Jun

    AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

  6. No Image 01Jun

    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

  7. No Image 01Jun

    Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

  8. No Image 01Jun

    Oscotec wins exception policy for continued R&D for new drugs

  9. No Image 01Jun

    Genosco gears up for IPO

  10. No Image 01Jun

    Oscotec`s acute leukemia treatment wins orphan drug status from FDA

  11. No Image 01Jun

    Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

  12. No Image 01Jun

    Yuhan ups investment in biotechs for immuno-oncology drug push

Board Pagination Prev 1 2 Next
/ 2
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.